[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-OKYO":3,"homepage-market-summary":30,"stock-news-OKYO":172},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":14},"OKYO","2026-10-07",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":9,"founded":9,"is_fund":13,"issuer":9,"category":9},"OKYO Pharma Limited Ordinary Shares","Nasdaq",null,"Common Stock","OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.","5",false,{"close":15,"open":16,"high":17,"low":18,"prev_close":19,"change":20,"percent_change":21,"volume":22,"transactions":23,"vwap":24,"high_52w":25,"low_52w":26,"avg_volume_52w":27,"range_52w_percent":28,"record_count":29},1.41,1.45,1.48,1.36,1.46,-0.05,-3.42,33738.541156,228,1.4178,3.2,1.2648,144936.05402334128,7.5,1102,{"status":31,"indices":32,"watchlist":75,"sectors":97,"benchmarks":152},"success",[33,40,47,54,60,67],{"symbol":34,"name":35,"price":36,"change":37,"pct_change":38,"is_up":13,"sparkline":39,"date":5},"SPX","S&P 500",7801.77,-17.16,-0.22,"0.0,13.9 2.3,10.5 4.6,12.4 6.9,14.2 9.3,16.0 11.6,11.5 13.9,10.8 16.2,4.8 18.5,4.8 20.8,7.9 23.2,8.0 25.5,6.0 27.8,9.1 30.1,9.8 32.4,10.8 34.7,10.0 37.1,7.0 39.4,4.4 41.7,2.0 44.0,2.9",{"symbol":41,"name":42,"price":43,"change":44,"pct_change":45,"is_up":13,"sparkline":46,"date":5},"NDX","NASDAQ 100",31160.08,-64.4,-0.21,"0.0,15.0 2.3,13.4 4.6,14.8 6.9,16.0 9.3,16.0 11.6,12.9 13.9,11.7 16.2,6.5 18.5,5.0 20.8,6.6 23.2,6.6 25.5,5.8 27.8,7.8 30.1,7.4 32.4,7.0 34.7,6.4 37.1,4.6 39.4,2.9 41.7,2.0 44.0,2.4",{"symbol":48,"name":49,"price":50,"change":51,"pct_change":52,"is_up":13,"sparkline":53,"date":5},"DJI","DOW JONES",51180,-341,-0.66,"0.0,6.3 2.3,2.0 4.6,3.3 6.9,6.0 9.3,11.3 11.6,8.7 13.9,9.5 16.2,6.4 18.5,8.0 20.8,10.9 23.2,12.3 25.5,8.2 27.8,11.2 30.1,12.3 32.4,16.0 34.7,15.8 37.1,13.7 39.4,13.0 41.7,10.8 44.0,13.7",{"symbol":55,"name":56,"price":57,"change":58,"pct_change":38,"is_up":13,"sparkline":59,"date":5},"COMP","NASDAQ Composite",27538.69,-61.2,"0.0,15.1 2.3,12.9 4.6,14.2 6.9,16.0 9.3,16.0 11.6,12.2 13.9,11.3 16.2,6.1 18.5,5.1 20.8,7.7 23.2,7.7 25.5,6.6 27.8,8.7 30.1,8.9 32.4,8.4 34.7,8.3 37.1,5.5 39.4,3.1 41.7,2.0 44.0,2.5",{"symbol":61,"name":62,"price":63,"change":64,"pct_change":65,"is_up":13,"sparkline":66,"date":5},"RUT","RUSSELL 2000",2777,-36.4,-1.29,"0.0,3.5 2.3,2.0 4.6,4.2 6.9,6.7 9.3,8.2 11.6,6.3 13.9,8.0 16.2,6.1 18.5,4.1 20.8,10.7 23.2,11.0 25.5,10.7 27.8,13.1 30.1,14.4 32.4,15.8 34.7,14.3 37.1,11.2 39.4,8.9 41.7,11.4 44.0,16.0",{"symbol":68,"name":69,"price":70,"change":71,"pct_change":72,"is_up":73,"sparkline":74,"date":5},"VIX","CBOE VIX",15.08,0.07,0.47,true,"0.0,2.0 2.3,9.7 4.6,4.9 6.9,4.5 9.3,2.5 11.6,11.3 13.9,13.7 16.2,13.5 18.5,16.0 20.8,12.3 23.2,10.4 25.5,13.5 27.8,8.8 30.1,8.9 32.4,7.8 34.7,7.6 37.1,11.8 39.4,10.9 41.7,12.9 44.0,12.6",[76,83,90],{"symbol":77,"name":78,"price":79,"change":80,"pct_change":81,"is_up":13,"sparkline":82,"date":5},"NVDA","NVIDIA Corp",237.36,-1.88,-0.79,"0.0,16.0 7.3,14.6 14.7,11.8 22.0,8.2 29.3,2.4 36.7,2.0 44.0,4.2",{"symbol":84,"name":85,"price":86,"change":87,"pct_change":88,"is_up":73,"sparkline":89,"date":5},"AAPL","Apple Inc",336.67,3.04,0.91,"0.0,16.0 7.3,9.0 14.7,14.2 22.0,7.7 29.3,9.3 36.7,7.9 44.0,2.0",{"symbol":91,"name":92,"price":93,"change":94,"pct_change":95,"is_up":13,"sparkline":96,"date":5},"TSLA","Tesla Inc",377.75,-2.93,-0.77,"0.0,16.0 7.3,15.0 14.7,15.4 22.0,7.1 29.3,3.0 36.7,2.0 44.0,3.5",[98,103,108,113,118,123,128,133,138,142,147],{"name":99,"etf":100,"change":101,"price":102,"is_up":13},"Technology","XLK",-0.3,201.39,{"name":104,"etf":105,"change":106,"price":107,"is_up":13},"Financials","XLF",-0.48,53.75,{"name":109,"etf":110,"change":111,"price":112,"is_up":73},"Healthcare","XLV",1.03,168.81,{"name":114,"etf":115,"change":116,"price":117,"is_up":13},"Consumer Cycl","XLY",-0.32,111.36,{"name":119,"etf":120,"change":121,"price":122,"is_up":13},"Consumer Staples","XLP",-0.12,81.7,{"name":124,"etf":125,"change":126,"price":127,"is_up":13},"Energy","XLE",-0.58,63.38,{"name":129,"etf":130,"change":131,"price":132,"is_up":13},"Industrials","XLI",-2.18,167.84,{"name":134,"etf":135,"change":136,"price":137,"is_up":13},"Materials","XLB",-1.51,48.98,{"name":139,"etf":140,"change":65,"price":141,"is_up":13},"Real Estate","XLRE",40.57,{"name":143,"etf":144,"change":145,"price":146,"is_up":13},"Utilities","XLU",-0.02,41.15,{"name":148,"etf":149,"change":150,"price":151,"is_up":13},"Comm Services","XLC",-0.35,111.26,[153,158,163,168],{"ticker":154,"name":155,"price":156,"change":157,"is_up":13},"SPY","SPDR S&P 500 ETF",777.22,-0.24,{"ticker":159,"name":160,"price":161,"change":162,"is_up":13},"QQQ","Invesco QQQ Trust",757.73,-0.25,{"ticker":164,"name":165,"price":166,"change":167,"is_up":13},"DIA","SPDR Dow Jones ETF",511.02,-0.69,{"ticker":169,"name":170,"price":171,"change":65,"is_up":13},"IWM","iShares Russell 2000",277.7,{"ticker":4,"count":173,"articles":174},9,[175,181,187,193,198,204,210,215,220],{"title":176,"link":177,"pubDate":178,"description":179,"source":180},"OKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo! Finance Canada","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiUkFVX3lxTFA1VVphSFlTZV93cE5fdUZ2dERaMnpoTE5SSERRQk5OazFxOGdCYzc1WnlhbU5TakdLczczeF82Y2QwdVVNNk1UbzBKT0tRRHAzUWc?oc=5","Tue, 06 Oct 2026 14:20:19 GMT","OKYO Pharma Limited (OKYO) Stock Price, News, Quote & History Yahoo! Finance Canada","Yahoo! Finance Canada",{"title":182,"link":183,"pubDate":184,"description":185,"source":186},"A planned trial for corneal nerve pain will enroll about 111 people; OKYO's CEO presents Oct. 8. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitgFBVV95cUxNRVZ6M1I3VE53Y21Yem9xZThuR1NSazRWdThkVzNnSUFPbVBOeEtON25DMmNsSm4taE9iZ0ZET3k2LTBSRzJBOEJfd2x5cWdMeW9DMVppQW91Z1N3endnbEN1NWg5UzQyU0t6eERtOXhrLWRpWFdEdWIyWlB3OXJiam9JSm1hMjc4NzhPMTVUbnFxbnNPOGhFVVY2aTZJQmYwSUkzdUJXNzV5NU9CaUFEaFhjekNYZw?oc=5","Tue, 29 Sep 2026 11:00:00 GMT","A planned trial for corneal nerve pain will enroll about 111 people; OKYO's CEO presents Oct. 8. Stock Titan","Stock Titan",{"title":188,"link":189,"pubDate":190,"description":191,"source":192},"OKYO Pharma Limited (OKYO) stock price, news, quote and history - Yahoo Finance UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiUkFVX3lxTE5iR3U0NnZCX0w2OHhvVGRPd21BTVg2eVRSRHU5b09Vb3Z2djd2Z2ZfaVRCSmxnN3BKeDlxSTdqbjhkNDNoSmJncVJPTDl2NjNlUlE?oc=5","Tue, 06 Oct 2026 17:43:42 GMT","OKYO Pharma Limited (OKYO) stock price, news, quote and history Yahoo Finance UK","Yahoo Finance UK",{"title":194,"link":195,"pubDate":196,"description":197,"source":186},"A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxQRjY2OU45UWNKWGxSUTR0UjFzMGtCTUp2UVF1R0R1Tkx4SWhUdm94bHFmaWxiRTFBd1FsSWlnaUpuc2RUMmhSc0FMSHVlQ2trUFJmeGFXYU04a3psOFd1NkRQMHVhcXdmano1ck14c214dE9jQmRzTTROTlRMUDJIejFXdG1nZ3VFNzJmYVFGTEhIYnJERVpTYjNsZ0gxekUzMlBTQS1Kc0N2bWdEV2tVcGRGSEhmQ0xnVjI0?oc=5","Tue, 06 Oct 2026 11:00:00 GMT","A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients. Stock Titan",{"title":199,"link":200,"pubDate":201,"description":202,"source":203},"H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment By Investing.com - Investing.com Canada","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiygFBVV95cUxNRWNSdFozVE41QVAtVXhzenZQTUVXaC1FQU0xVnpCRkNodFhvc3Z4TTZmN1ZGOGhEU3NhSWQxNFFjdEkzdHdiWC1iUDdQRU1yNHFNQlpYLXRMWU5lYVJ5MGFoMnUtNzZYUllYYkxVZWpaMzJ0aEphMkMwc2FSaG5PbDhpbzVtZ1lQQ3VhdVlVZ1lhNUctSVZ4MzdHN2ZuSS1MMDdXaHl3WFAtR0RuWDNCZ0M3Z2wyWXVmU1AyeUdvci15bVdQNThnZmpR?oc=5","Wed, 07 Oct 2026 11:44:34 GMT","H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment By Investing.com Investing.com Canada","Investing.com Canada",{"title":205,"link":206,"pubDate":207,"description":208,"source":209},"OKYO Pharma starts Phase 3 trial for neuropathi... - Pluang","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMilgFBVV95cUxQenkxRzFyVWxZNUx5MThKbnNlTXM4XzJzZW5sa3F4cHY4X0hkNXVrM09pLVQyMUhwdjFBYWpwclEtLU5UREZoZ2syWUlGdUMwYmdwNFRPWnFMLUFXX3pCd0FnYng2UGlPeVRuZFJCT0hNWWthUk9jX21LbHgtSVBnby1WT3FmdE0wM3Q2eWg3TGdmck9BMFE?oc=5","Tue, 06 Oct 2026 12:58:49 GMT","OKYO Pharma starts Phase 3 trial for neuropathi... Pluang","Pluang",{"title":211,"link":212,"pubDate":213,"description":214,"source":186},"A single-dose eye pain treatment is slated for a global trial at OKYO Pharma (OKYO). - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMisAFBVV95cUxPdFVpLWxEVTZxWjYxcVViYWFVcDhDa1FJN2VvZWhJYll0VE5FbkFVNTFxdmVqWVR3RTB2Y0hFMzVESE9nUUtEY3dZeVhBdFZjZXJkTU14YVVvMHNXT2ZELWJDOWUxUzhIbGpjVGpZSUhCbGVGN1BveUczeXF5dzd0OWxhLTd3VmNIVHBmc1VPUEFkU0c3aHE3U0xSZmN2dVoya2E5ZnlXbVdnNk1FdlJqSQ?oc=5","Tue, 29 Sep 2026 11:00:42 GMT","A single-dose eye pain treatment is slated for a global trial at OKYO Pharma (OKYO). Stock Titan",{"title":216,"link":217,"pubDate":218,"description":219,"source":186},"First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMisAFBVV95cUxOTUxTdmE4WHlxY3Z6RkJuSjliNEswbVBSZnQzbmRjOGEtVEdvUWc3VzZwY0tpcnZLNU5WblNoOFpXT3RTbHhJSUJSb3lDOFJGaGlfc3gtZTE5aElDSjVaZ0xrdHRpNFNEQUFKbFh3Rjgzc2hCM1lsdzFmenZoLUxTX2JpUF8zQ3BBTGVzLUZPVVYxNl82RTBtcXpMRzk0VlhRRlFKMU9yYk5VSlNUeGxiVA?oc=5","Tue, 06 Oct 2026 11:00:26 GMT","First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. Stock Titan",{"title":221,"link":222,"pubDate":223,"description":224,"source":225},"OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi6AFBVV95cUxNVjFQekJMVUE2QTNnOEktYXBEb20xU0ZpLUE5bWJocFFEaFdYcTN3cXRZd29hQVlaNlBENTlmREJ1X3AybG5jX002OEpnYk9UY3lVUlBSQ1otWmtQTW1YV3JNOEUtcElXWEVySC1JVEtZVnlaZkswSjgyeXVsenpWb0liNFYwTlZiemhZSnFIcnBCLVM0ZEVsZjA4OEY3cE5Ed1kxY0N6bVRLR09hZjZYcGpUNVViUEQxNlJtbXY5djBjTGc2WEVYRmk4Q0UtbVMyOFg0WjJkVGo4VV91N3BtTUdCeVdDQWtK?oc=5","Tue, 06 Oct 2026 11:41:58 GMT","OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain TipRanks","TipRanks"]